© Copyright 2012, vLex. All Rights Reserved.
- Language
Contents in vLex United States
Explore vLex
For Professionals
For Partners
Company
Michael Krensavage
10 documents for Michael Krensavage
-
head-on competition is not what we are trying to do at Medimetriks," says Glassman, who chairs the new company. "It just happens that I am most familiar in dermatology." Medimetriks "will be competing" with Bradley, he adds, but also plans to develop products that won't compete with his former company. Mark Lebwohl, chairman of the dermatology department at the Mount Sinai School of Medicine in New York City notes that "with the exception of the biologies companies that are making drugs for psoriasis, most of the large companies like Novartis, Roche and GlaxoSmithKline have abandoned dermatology, so there is a huge void and an opening for small companies," Lebwohl says. Bradley Glassman thinks the business can produce gross margins of 75 percent or more, and could turn cash-flow posit...
...Michael Krensavage, partner at Krensavage Partners LP, a h...
-
Marketing strategy - Cover Story
... of New York-based Jefferies & Co., and Michael Krensavage of St. Petersburg, Fla.-based Raymond J...
-
Wyeth in a June 2 presentation confirmed the opinion that its pipeline - combined with a lack of patent expirations - will allow it to produce earnings growth at least as swift as its peers for the next five years. Wyeth's next potentially significant new drug is bazedozifene, a treatment for osteoporosis. The company hopes to file for approval next year.
-
File two lawsuits and call me in the morning. That has been the prescription for dealing with drug side effects lately. As a result, the pharmaceutical industry is in a fever over class-action suits, large settlements and Food and Drug Administration actions.
... some of the new drugs that it has," said Michael Krensavage, New York-based pharmaceutical analyst ...
-
Prescription prices up Pharmaceutical companies raised wholesale prices an average of 7.82 percent in 2007, but a few drugs had price increases well above that rate Antidepressant Wellbutrin XL (made by GlaxoSmithKline), from 2005 to 2007 44.5% Sleep drug Ambien (made by Sanofi-Aventis SA) 70.1% ADD drug Adderall XR (made by Shire PLC) 33.5% Cholesterol drug Lipitor (made by Pfizer Inc.) 16% The pharmaceutical industry has been a frequent target in the current presidential campaign, but that hasn't stopped it from continuing to aggressively raise the prices of prescription drugs.
... by making old ones so expensive," says Michael Krensavage, a drug-industry analyst with Raymond J...
-
Merck & Co. Inc.'s stock continued to fall yesterday in the wake of the pharmaceutical giant's loss of its first Vioxx lawsuit. The Whitehouse Station, N.J., company, which faces about 4,200 lawsuits over the arthritis painkiller, on Friday was found liable for the 2001 death of a Texas man who took the drug for eight months.
...But analyst Michael Krensavage said investors overreacted to the jury'...
-
... way as Raymond James Associates analyst, Michael Krensavage announced that he was evaluating the im...
-
Bradley Pharmaceuticals Inc.'s first product acquisition in five years certainly made a splash. Shares of the Fairfield-based niche player skyrocketed Wednesday after it announced a $183 million acquisition to boost its booming dermatology business.
...Michael Krensavage, an analyst with Raymond James, said th...
-
Money Matters - AaiPharma Inc.
... to pay more attention to New York-based Michael Krensavage, the analyst who trashed it. He called ...
-
...analyst Michael Krensavage on RadioWallStreet today, Tuesday, June...
